The identification of natural compounds with favorable binding properties to the GluN1 subunit, as demonstrated in our molecular docking studies, may provide new avenues for developing safer and more effective treatments for GRIN1-related neurodevelopmental disorders. The gene discussed is GRIN1; the disease is neurodevelopmental disorder.